All News

Voranigo plus Temodar was safe in glioma with IDH1/2 mutations.

Early data from the SJ901 study show Gomekli generates responses with manageable side effects in children and young adults with low grade glioma.

Early data indicate Voranigo is rapidly being used in newly diagnosed and previously treated patients with IDH-mutant glioma, highlighting ongoing treatment needs.

Researchers identified a potential unmet need for an effective early treatment with minimal toxicity for patients with slow-growing IDH-mutant gliomas.

Keytruda and Padcev improve event-free and overall survival for adults with muscle invasive bladder cancer who cannot receive cisplatin after surgery.

In a recent interview with CURE, Nona Baker shared insights from her blood cancer journey that began more than 30 years ago.

Giredestrant improved invasive disease-free survival for people with estrogen receptor-positive early breast cancer compared with standard treatment.

I share how the nurses who cared for my daughter during chemotherapy brought comfort, connection and humanity that carried us through our hardest moments.

Immune-based therapies are transforming advanced liver cancer care, resulting in curative options previously considered unattainable.

Dr. Anne Chiang explains how biomarker testing and molecular profiling personalize lung cancer treatment and compare tissue versus liquid biopsies.

After surviving testicular cancer, I feel like I was given a second chance at life. Although given challenges, I have learned to be resilient and face adversity head-on.

Dr. Ajay Gupta sat down with CURE to explain the basics of gastrointestinal stromal tumors, highlighting what patients with this disease need to know.

The FDA accepted a new drug application for zidesamtinib for previously treated locally advanced or metastatic ROS1-positive non-small cell lung cancer.

Dr. Michael Staehler highlighted nutrition’s role in kidney cancer, noting that diet, stress management, and lifestyle can impact outcomes and well-being.

I reflect on my brain tumor journey, sharing how gratitude, love and connection with my parents and others strengthened me through difficult times.

The FDA has approved Hyrnuo for some with locally advanced or metastatic non-squamous non–small cell lung cancer with activating mutations.

The FDA approved Imdelltra after a study showed longer survival compared with chemotherapy in advanced small cell lung cancer.

I never dreamed a stranger could teach me so much about cancer, life and living with gratitude but I'm so glad she did!

Dr. Jorge E. Cortes discussed the evolution of chronic myeloid leukemia treatment and emerging strategies aimed at improving outcomes and quality of life.

The oral therapy DPTX3186 received fast track status to help speed development of a potential new option for patients with gastric cancer.

Dr. Pamela L. Kunz sat down with CURE to discuss Neuroendocrine Tumors, or NETs, Awareness Month.

Dr. Benjamin Herzberg spotlighted some of the “weird and wacky” new ideas in the field of targeted therapies for the treatment of lung cancer.

A podcast from Triage Health simplifies health insurance and finances to help people facing serious illness make informed, confident decisions.

Dr. Adam J. Schoenfeld delivered an extensive overview of how cellular therapies are shaping the future of lung cancer care.

Dr. Catherine A. Shu highlights targeted therapies for patients with lung cancer, emphasizing advances, challenges and the importance of clinical trials.

Many fail to recognize that estrogen is necessary to help your body and its parts work in concert with each other seamlessly.  

The FDA has granted fast track designation to ITM-94 as a diagnostic agent for the detection of the most common type of kidney cancer.

The FDA has approved Epkinly plus Revlimid and Rituxan for the treatment of patients with relapsed or refractory follicular lymphoma.